Feraccru is a unique, non-salt, formulation oral iron: strong efficacy with “placebo-like” tolerability
Potential to change iron deficiency anaemia (IDA) therapeutic algorithm
Feraccru to become the preferred option for patients not adequately controlled or who are intolerant to generic oral iron supplements (before they switch to intravenous iron).
With an indication in Europe to treat iron deficiency, Feraccru’s use would prevent the occurrence/reoccurrence of iron deficiency anaemia
Feraccru European commercialisation expected to accelerate significantly following the licensing agreement with Norgine announced in September 2018
Key upcoming milestones: results of the head-to-head phase 3 study of Feraccru vs intravenous (i.v.) iron expected in first half (1H) of 2019; Feraccru PDUFA (Prescription Drug User Fee Act) date 27 July 2019
Current market capitalisation of about £40mln is by and large not reflecting Feraccru commercial potential